Read by QxMD icon Read

Mood stabilizers

Ashley L Greene, Nicholas R Eaton
BACKGROUND: Structural models of psychopathology indicate that common mental disorder comorbidity reflects latent transdiagnostic factors. Multiple studies have replicated transdiagnostic internalizing (mood and anxiety disorders) and externalizing (substance use, antisociality-, and impulsivity-related disorders) factors; other studies support distress and fear sub-factors of internalizing. These factors show a high degree of temporal stability. Recently, a bifactor conceptualization of multivariate comorbidity has emerged, positing the existence of an orthogonal general psychopathology factor that saturates all diagnoses in addition to internalizing/distress/fear and externalizing, although no studies have examined the temporal stability of the factors in this competing model over time among adults...
September 28, 2016: Comprehensive Psychiatry
Yuan Feng, Sha Sha, Chen Hu, Gang Wang, Gabor S Ungvari, Helen F K Chiu, Chee H Ng, Tian-Mei Si, Da-Fang Chen, Yi-Ru Fang, Zheng Lu, Hai-Chen Yang, Jian Hu, Zhi-Yu Chen, Yi Huang, Jing Sun, Xiao-Ping Wang, Hui-Chun Li, Jin-Bei Zhang, Yu-Tao Xiang
INTRODUCTION: Little has been reported about the demographic and clinical features of major depressive disorder (MDD) with comorbid dysthymia in Chinese patients. This study examined the frequency of comorbid dysthymia in Chinese MDD patients together with the demographic and clinical correlates and prescribing patterns of psychotropic drugs. METHODS: Consecutively collected sample of 1178 patients with MDD were examined in 13 major psychiatric hospitals in China...
October 19, 2016: Asia-Pacific Psychiatry: Official Journal of the Pacific Rim College of Psychiatrists
Lola Corzo, Susana Rodríguez, Ramón Alejo, Lucía Fernández-Novoa, Gjumrakch Aliev, Ramón Cacabelos
Menopause is a natural event in women´s lives leading to the cessation of menstruation and the reproductive function due to loss of the ovarian follicular function. Menopause-derived estrogen deprivation and related endocrine factors are linked to some symptoms of middle-aged women, such as hot flashes, aches, joint pain, stiffness, depressed mood, bone degeneration, nutritional dysfunction, or difficulty to maintain body mass. Clinical approaches to these problems often involve hormone replacement therapy (HRT) and other modalities of therapeutic intervention...
October 14, 2016: Current Drug Metabolism
Kamini Rajaratnam, Yu-Tao Xiang, Adarsh Tripathi, Helen Fung Kum Chiu, Tian-Mei Si, Kok-Yoon Chee, Ajit Avasthi, Sandeep Grover, Mian-Yoon Chong, Hironori Kuga, Shigenobu Kanba, Yan-Ling He, Min-Soo Lee, Shu-Yu Yang, Pichet Udomratn, Roy Abraham Kallivayalil, Andi J Tanra, Margarita Maramis, Winston Wu-Dien Shen, Norman Sartorius, Ee-Heok Kua, Chay-Hoon Tan, Rathi Mahendran, Naotaka Shinfuku, Min Yi Sum, Ross J Baldessarini, Kang Sim
In this study, we sought to examine factors associated with dosing of antidepressants (ADs) in Asia. Based on reported data and clinical experience, we hypothesized that doses of ADs would be associated with demographic and clinical factors and would increase over time. This cross-sectional, pharmacoepidemiological study analyzed data collected within the Research Study on Asian Psychotropic Prescription Pattern for Antidepressants from 4164 participants in 10 Asian countries, using univariate and multivariate methods...
October 5, 2016: Journal of Clinical Psychopharmacology
Martina Hahn, Sibylle C Roll
A 50-year-old male patient with comorbid human immunodeficiency virus developed a relapse of bipolar disorder after a switch from oral aripiprazole 10 mg/day to intramuscular aripiprazole depot 200 mg every 28 days plus oral aripiprazole 5 mg/day. The patient was concomitantly taking lopinavir, saquinavir, ritonavir, silybum marianum extract, and omeprazole. Only 1 week after the switch, the patient developed mood swings, irritability, depressive mood, and lack of drive. The oral aripiprazole was increased again to stabilize the patient...
December 2016: Drug Saf Case Rep
Leila Mnif, Rim Sellami, Jawaher Masmoudi
BACKGROUND: Valproic acid is a mood-stabilizing anticonvulsant. Hepatic injuries are among the occasionally observed adverse effects of this medication. CASE PRESENTATION: We present the case of a 47-year-old man who had bipolar disorder for ten years and treated with valproic acid. He demonstrated elevated serum aminotransferases and ultrasonography revealed that hepatomegaly was suggestive of hepatic steatosis. CONCLUSION: This case report stresses the importance of a complete drug history and the need for clinicians to be aware of the delayed onset of hepatic injuries...
August 15, 2016: Psychopharmacology Bulletin
M Lambert, V Niehaus, C Correll
This review aims to describe the importance of i) detecting individuals at clinical high-risk for psychosis (schizophrenia) or bipolar disorder, especially in children and adolescents, in order to enable early intervention, and ii) evaluating different intervention strategies, especially pharmacotherapy, during the subsyndromal or "prodromal" stages of these severe and often debilitating disorders. The different approaches regarding the psychotic and bipolar clinical high-risk state are discussed, including reasons and evidence for early (pharmacological) intervention and risks of treatment vs...
October 13, 2016: Pharmacopsychiatry
Leena Kovanen, Kati Donner, Mari Kaunisto, Timo Partonen
BACKGROUND: Dysfunctions in the intrinsic clocks are suggested in patients with depressive disorders. The cryptochrome circadian clocks 1 and 2 (CRY1 and CRY2) proteins modulate circadian rhythms in a cell and influence emotional reactions and mood in an individual. The protein kinase C delta binding protein (PRKCDBP, or CAVIN3), similar to the serum deprivation response protein (SDPR, or CAVIN2), reduces metabolic stability of the PER2-CRY2 transcription factor complex that plays a role in the circadian rhythm synchronization...
September 28, 2016: Journal of Affective Disorders
Fiona C A Geraerts, Russell G Snell, Richard L M Faull, Liam Williams, Jessie C Jacobsen, Suzanne J Reid
Huntington's disease is caused by expansion of the CAG repeat in Huntingtin. This repeat has shown tissue-specific instability in mouse models and in a small number of post-mortem human samples. We used small-pool PCR to generate a modified instability index to quantify CAG instability within two brain regions from six human samples where cell loss has been associated with motor and mood symptoms: the motor cortex and cingulate gyrus. The expanded allele demonstrated instability in both regions, with minimal instability in the unexpanded allele...
October 1, 2016: Journal of Huntington's Disease
Alexander Viktorin, Eleonore Rydén, Michael E Thase, Zheng Chang, Cecilia Lundholm, Brian M D'Onofrio, Catarina Almqvist, Patrik K E Magnusson, Paul Lichtenstein, Henrik Larsson, Mikael Landén
OBJECTIVE: The authors sought to determine the risk of treatment-emergent mania associated with methylphenidate, used in monotherapy or with a concomitant mood-stabilizing medication, in patients with bipolar disorder. METHOD: Using linked Swedish national registries, the authors identified 2,307 adults with bipolar disorder who initiated therapy with methylphenidate between 2006 and 2014. The cohort was divided into two groups: those with and those without concomitant mood-stabilizing treatment...
October 3, 2016: American Journal of Psychiatry
Marco Solmi, Nicola Veronese, Leonardo Zaninotto, Marc L M van der Loos, Keming Gao, Ayal Schaffer, Catherine Reis, Claus Normann, Ion-George Anghelescu, Christoph U Correll
OBJECTIVES: To meta-analytically summarize lamotrigine's effectiveness and safety in unipolar and bipolar depression. METHODS: We conducted systematic PubMed and SCOPUS reviews (last search =10/01/2015) of randomized controlled trials comparing lamotrigine to placebo or other agents with antidepressant activity in unipolar or bipolar depression. We performed a random-effects meta-analysis of depression ratings, response, remission, and adverse effects calculating standardized mean difference (SMD) and risk ratio (RR) ±95% confidence intervals (CIs)...
October 2016: CNS Spectrums
Glenda M MacQueen, Katherine A Memedovich
Cognitive dysfunction is a recognized feature of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). Cognitive impairment is associated with poor overall functional outcome and is therefore an important feature of illness to optimize for patients' occupational and academic outcomes. While generally people with BD appear to have a greater degree of cognitive impairment than those with MDD, direct comparisons of both patient groups within a single study are lacking. There are a number of methods for the assessment of cognitive function, but few are currently used in clinical practice...
September 29, 2016: Psychiatry and Clinical Neurosciences
Carlos Costa, Ana Margarida Pinto, Ana Telma Pereira, Mariana Marques, António Macedo, José António Pereira da Silva
BACKGROUND: Fibromyalgia (FM) remains a relatively misunderstood and clinically challenging condition that impact significantly in the individual´s life, impairing global functioning and diminishing quality of life. Management is complex and frequently unsatisfactory, requiring personal tailoring and adaptation of interventions according to the fluctuations of the disease manifestations and their response to therapy. The use of comprehensive and quantified assessment tools constitutes, therefore, an essential component of the management of patients with FM...
April 23, 2016: Acta Reumatológica Portuguesa
Anindya Bhattacharya, Wayne C Drevets
Mood disorders are associated with persistently high rates of morbidity and mortality, despite the widespread availability of antidepressant treatments. One limitation to extant therapeutic options has been that nearly all approved antidepressant pharmacotherapies exert a similar primary action of blocking monoamine transporters, and few options exist for transitioning treatment resistant patients to alternatives with distinct mechanisms. An emerging area of science that promises novel pathways to antidepressant and mood-stabilizing therapies has followed from evidence that immunological factors play major roles in the pathophysiology of at least some mood disorder subtypes...
September 28, 2016: Current Topics in Behavioral Neurosciences
Enrico Paolini, Francesca Alice Fiore Mezzetti, Francesca Pierri, Patrizia Moretti
OBJECTIVE: Borderline personality disorder (BPD) is a high prevalence personality disorder. Pharmacotherapy is commonly used, however, a minority of studies investigated patterns of prescription for BPD, particularly in inpatients unit. We aimed to describe the clinical features and the prescribing practice for BPD patients, and to investigate the possible advantages of a single class of medications or of combined drug treatments in terms of length of stay in hospital. METHODS: This is a retrospective observational study evaluating 109 BPD inpatients from June 2011 to June 2013...
September 27, 2016: International Journal of Psychiatry in Clinical Practice
Gopalkumar Rakesh, Jagadisha Thirthalli, Channaveerachari Naveen Kumar, Kesavan Muralidharan, Vivek H Phutane, Bangalore N Gangadhar
BACKGROUND: Electroconvulsive therapy (ECT) is an effective treatment for major affective disorders. The combined use of ECT and anticonvulsant mood stabilizers is a common clinical scenario. There is dearth of systematic studies on the use of this combination with regard to clinical or cognitive outcomes. OBJECTIVE/HYPOTHESIS: We aimed to compare clinical improvement and cognitive adverse effects between patients who received only ECT versus those who received ECT and anticonvulsants...
September 23, 2016: Journal of ECT
Francesco Franza
BD-II has been consistently associated with cognitive dysfunction across a broad range of cognitive domains. Atypical antipsychotic drugs, or SGAs are effective antipsychotics in these diseases, often in combination with antidepressants and mood stabilizers. Data on the possible effect of antipsychotics on neuro-cognition are rare and conflicting. The main objective of our study was to assess the effectiveness and possible risks to cognitive function in a group of inpatients affected by BD-II. Forty-five inpatients with Bipolar II Disorder (DSM-5) were included in a two-year observational study...
September 2016: Psychiatria Danubina
H Brochard, C Boudebesse, C Henry, O Godin, M Leboyer, B Étain
OBJECTIVE: To examine the pathophysiologic mechanisms that may link circadian disorder and metabolic syndrome in bipolar disorder (BP). METHOD: A systematic review of the literature was conducted from January 2013 to January 2015, using the Medline and Cochrane databases, using the keywords "metabolic syndrome", "obesity", "leptin" and "circadian disorders", "sleeping disorders" and cross-referencing them with "bipolar disorder". The following types of publications were candidates for review: (i) clinical trials; (ii) studies involving patients diagnosed with bipolar disorder; (iii) studies involving patients with sleeping disorder; or (iv) data about metabolic syndrome...
September 20, 2016: L'Encéphale
F Sauvanaud, O Kebir, M Vlasie, V Doste, I Amado, M-O Krebs
INTRODUCTION: In schizophrenic disorders, supportive psychosocial therapies have been used as adjuncts to pharmacotherapy to help alleviate residual symptoms and to improve social functioning and quality of life. Among these therapies, psychoeducational therapies showed a significant efficacy on improving drug adherence and on reducing relapses. However, according to the French Health Agency, fewer than 10% of psychiatric structures in France offer registered psychoeducation programs...
September 19, 2016: L'Encéphale
Monika Szkultecka-Dębek, Katarzyna Miernik, Jarosław Stelmachowski, Miro Jakovljević, Vlado Jukić, Kaire Aadamsoo, Sven Janno, István Bitter, Judit Tolna, Marek Jarema, Slobodan Jankovic, Jan Pecenak, Livia Vavrusova, Rok Tavčar, Jacek Walczak, Darren Talbot, Joanna Augustyńska
OBJECTIVE: The aim is to analyze how schizophrenia is pharmacologically treated in seven CEE countries: Croatia, Estonia, Hungary, Poland, Serbia, Slovakia and Slovenia. METHODS: Psychiatrists from selected centers in each of participating countries were asked to complete a pre-defined questionnaire on their current clinical practice. Information on protocols and resource utilization in schizophrenia treatment was included and derived from randomly selected patient medical records...
September 2016: Psychiatria Danubina
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"